News

ISOThrive Awarded Composition of Matter and Production Method Patent for its First “Farmaceutical™” to Support Animal Health

ISOThrive Inc., a microbiome therapeutics company announced that the U.S. Patent and Trademark Office has issued a Composition of Matter and Production Method patent for its first Farmaceutical™ Maltosyl-Isomaltooligosaccharides (MIMO™), a prebiotic for use as an animal feed additive and pet food supplement. USDA and University of GA studies showed MIMO as highly effective at protecting chickens against antibiotic resistant Salmonella while improving feed efficiency.

ISOThrive opens up a whole new market opportunity to offer higher quality meats that are free of pathogens and also leaner. At the same time, increased food safety is better for workers, less costly for producers and better for the environment. Plus, there are emerging opportunities in pet health with supplements that support better digestion with less reliance on medications.

The widespread use of antibiotics in cattle, swine and chickens can lead to the creation of antibiotic resistant bacterial species.  The same antibiotics used in animal feed are also used to treat disease in humans. With the rise of antibiotic resistant bacteria, eliminating their use in livestock has become a necessity. Prebiotics, while offering a viable alternative to antibiotics, can be expensive to manufacture. This patent covers an economical and efficient method for making (MIMO) that can be used as an additive for animal feed at significantly lower cost.

“Today’s conscious consumer wants a healthier food supply, a better environment for the people that produce the food and has the least amount of environmental impact,” said Jack Oswald, ISOThrive’s CEO, CTO and Co-Founder. “This new patent allows us to open a new market opportunity while simultaneously positively impacting food safety and security at a cost that makes sense for producers.”

Researchers at USDA and University of Georgia found that MIMO added to chicken feed reduced antibiotic resistant Salmonella by 99% while increasing Bifidobacteria.  Feed efficiency was increased by 9-10%.

 

Recent News

07/19/2024

Capra Biosciences Lands $7.5 Million Project Agreement To Demonstrate Platform To Rapidly Scale Pharmaceutical Ingredient Manufacturing

Many ingredients that make up the pharmaceuticals Americans rely on are manufactured overseas. When supply chain issues or shortages occur, as witnessed during the COVID pandemic, it can negatively impact millions of Americans and affect national security. The White House issued an Executive Order in 2022 to stimulate U.S. biomanufacturing. Increasing American biomanufacturing, will provide

07/15/2024

Lupus Treatment with Omega3-Rich Krill Oil Improves Disease Activity

AMPEL BioSolutions, with collaborators Lupus Therapeutics and Aker Biomarine, revealed peer-reviewed results that supplementation with Omega3-rich Krill Oil improves disease activity of autoimmune Lupus patients. Omega3 lipids called polyunsaturated fatty acids (PUFAs) that are found in microscopic shrimp-like crustaceans called Krill from the waters around Antarctica are key to maintaining a low inflammatory state.  Some

07/15/2024

Inorganic Ventures acquires PURE Analytical Laboratories, Combining Unique Capabilities for Precision Manufacturing

Two privately held specialty chemical firms that provide high-purity materials and services for chemical applications, from renewable energy to food and beverages and consumer safety, are combining their capabilities to serve new and expanding precision markets. IV Labs Inc., the parent company of Inorganic Ventures, has acquired PURE Analytical Laboratories, one of the few companies that